Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
- Mar 5, 2024
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC...
- Feb 28, 2024
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta...
- Jan 18, 2024
Data from the Pivotal Phase 3 CLEAR Trial and Phase 2 KEYNOTE-B61 Trial Provide Further Insight into the Role of Lenvatinib Plus Pembrolizumab as a First-Line Treatment Option for Patients with...
- Jan 16, 2024
Longer-Term Efficacy and Safety Results from the Phase 3 LEAP-002 Trial Offer Additional Information About the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma Data on...
- Oct 25, 2023
INVESTIGATIONAL SUBCUTANEOUS FORMULATION CLEARS 14% MORE PLAQUE THAN IV, PHARMACOKINETICS (AUC) 11% HIGHER, AND SIMILAR ARIA RATES TO IV 76% OF PATIENTS SHOWED NO DECLINE AND 60% SHOWED CLINICAL...
- Oct 24, 2023
Eisai Inc. and Biogen Inc. are honored to announce today that TIME has selected LEQEMBI® (lecanemab-irmb) as one of the Best Inventions of 2023 in the Medical Care category. LEQEMBI is the first...
- Oct 15, 2023
Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present new data from the phase 3 Clarity AD study for its Alzheimer's disease (AD) treatment...
- Oct 11, 2023
Data from the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Provide Valuable Information About the Treatment of Patients with Advanced Renal Cell Carcinoma and Certain Types of Advanced...
- Aug 17, 2023
Efforts Aimed to Help Sustain the Environment, Boost Employee Health & Wellness NUTLEY, N.J., Aug. 17, 2023 /PRNewswire/ -- Eisai Inc., the United States-based pharmaceutical subsidiary of Eisai...
- Jul 19, 2023
Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer's disease New data on subcutaneous formulation shows promising...
- Jul 11, 2023
Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including...
- Jul 6, 2023
The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer's disease The Centers for Medicare &...
- Jun 9, 2023
Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer's...
- May 23, 2023
Final Pre-Specified Overall Survival Analysis from the Pivotal Phase 3 CLEAR Trial in Patients with Advanced Renal Cell Carcinoma Will Be Featured in an Oral Presentation NUTLEY, N.J., May 23,...
- Apr 11, 2023
Initiative Features Compelling Stories Celebrating That People are "Made of More" Than Their Head and Neck Cancer Diagnosis, Along With Resources to Help People Impacted Find Support and Community...
- Apr 3, 2023
Treatment with Lecanemab Resulted in a Delay of 2 to 3 Years in the Mean Time to Progression to More Severe Stages of Alzheimer's Disease, Compared with Standard of Care Alone Subgroup Analysis...
- Mar 30, 2023
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...
- Mar 30, 2023
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...
- Mar 23, 2023
Study Findings in Patients with Recurrent or Advanced Endometrial Carcinoma Who Were Rechallenged With Platinum Chemotherapy Will Be Featured in an Oral Plenary Session Additional Subgroup...
- Mar 22, 2023
Presentations Explore ARIA with the Use of Antiplatelets or Anticoagulants and Isolated ARIA-H in Patients from Eisai's Lecanemab Phase 3 Confirmatory Clarity AD Study in Early Alzheimer's Disease...
- Mar 19, 2023
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta (Aβ)...
- Mar 13, 2023
Eisai is Proud to Support U.S. Veterans Living with Early Stages of Alzheimer's Disease and Will Continue to Transparently Share our High-Quality Data with the VHA TOKYO, March 13, 2023...
- Mar 5, 2023
Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval Priority Review accelerates FDA review time...
- Feb 27, 2023
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...
- Jan 29, 2023
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")...